Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lei Nie, Lin Wu et al.|Journal of Clinical Oncology|2022Cited by 177
Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancerYali Yi, Anwen Liu|Journal of Translational Medicine|2022Cited by 26
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical studyYanxin Chen, Anwen Liu|Cancer Immunology Immunotherapy|2025Cited by 10
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contentionYi‐Long Wu, Qitao Yu, Shun Lü et al.|Medicine Advances|2023Cited by 8
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancerDingzhi Huang, Qian Miao, Baoshan Cao et al.|Thoracic Cancer|2023Cited by 5